Angioimmunoblastic T-cell lymphoma (AIL-TCL) is a rare subtype of lymphoma, making up only 1% to 2% of nonHodgkin's lymphomas; however, it accounts for a major subset of peripheral T-cell lymphomas. Angioimmunoblastic T-cell lymphoma has clinical and pathologic features that set it apart from other B-and T-cell lymphomas. More recent studies have delineated the immunophenotypic and genetic features of this unusual lymphoma, and have tentatively identified the cell of origin of this neoplasm.
INTRODUCTION
Angioimmunoblastic T-cell lymphoma was first described as angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) by Frizzera (1) and subsequently as immunoblastic lymphadenopathy by Lukes and Tindle (2) . Initially, the disorder was thought to be an abnormal immunologic reaction or an atypical reactive process, but later studies demonstrated the presence of clonal T-cell receptor gene rearrangements and clonal cytogenetic abnormalities (3) (4) (5) , leading to an interpretation of T-cell lymphoma. Angioimmunoblastic T-cell lymphoma is recognized as a distinct entity in the World Health Organization (WHO) classification (6) , where it is classified as a mature T-cell neoplasm. It represents one of the three T-cell lymphomas with primarily nodal presentation, along with peripheral T-cell lymphoma, unspecified type, and anaplastic large cell lymphoma (6) ( Table 1 ). The differential diagnosis of AIL-TCL is broad, and includes atypical reactive processes, Hodgkin's disease (HD), B-cell lymphomas, and other peripheral T-cell lymphomas. Recent advances in the study of AIL-TCL have disclosed a characteristic immunophenotype that appears helpful in differential diagnosis.
DISCUSSION

Clinical Features
Patients with AIL-TCL are mostly older adults. Their ages range from the third to the ninth decade; the majority are over age 60. Males and females are equally affected (1, 4, (7) (8) (9) (10) (11) (12) (13) (14) (15) . They present with acute onset of generalized peripheral lymphadenopathy, usually accompanied by hepatosplenomegaly, and almost always accompanied by systemic symptoms including fever, chills, night sweats, malaise, anorexia, weight loss, or a combination of these (1, 4, 9, (11) (12) (13) (14) . Many patients also have mediastinal and retroperitoneal lymphadenopathy (12) . Up to approximately half of patients have a rash, pruritus, or both. The rash is usually described as a generalized morbilliform or maculopapular eruption (1, 8, 13, 16) . Nodular lesions, plaques, purpura, and urticarial lesions have also been described, but are less common (1, 12, 16) .
Patients also have a characteristic set of laboratory abnormalities. Most have a normochromic, normocytic anemia, and the anemia is often a Coombs' positive hemolytic anemia. Leukocytosis, with neutrophilia or eosinophilia, and lymphopenia are common. The vast majority has a polyclonal hypergammaglobulinemia. More than half have an elevated lactate dehydrogenase (1, 8, (11) (12) (13) (14) . Patients may also have circulating immune complexes, cold agglutinins, paraprotein, rheumatoid factor, antismooth muscle antibodies, and elevated eryth-rocyte sedimentation rate (8, 17) . A substantial minority of patients are found to have peripheral edema, pleural effusion, ascites, or arthritis (4, 8) . In some patients, the onset of the disease has appeared to coincide with drug or chemical exposure (1, 12, 14, 17) .
In addition to lymph nodal involvement, and frequent hepatic and splenic involvement, AIL-TCL involves the bone marrow in approximately two-thirds of cases. The lymphoma may also involve the lungs (4, 11) , and rarely involves the gastrointestinal tract (18, 19) . Patients have stage III or IV disease in 90% or more of cases (8, 10, 12, 13) . Patients have a significant immunodeficiency related to T-cell dysfunction. The immunodeficiency appears to be secondary to the lymphoma rather than being a preexisting immunodeficiency that predisposes to the development of lymphoma (1, 6) .
The prognosis for AIL-TCL patients is poor, with a median survival of less than 3 years (4,6,8,10,12). Patients have been treated with combination chemotherapy, steroids, alpha interferon, or a combination of these modalities, and more than half of patients achieve a complete remission. Most who attain a remission relapse, and they, as well as nearly all of those who do not achieve a remission, succumb to lymphoma or to infection (sepsis, pneumonia, meningoencephalitis, due to Gram-positive bacteria, Gram-negative bacteria, cytomegalovirus, mycobacteria, or fungi). The immunodeficiency associated with AIL-TCL complicates attempts to treat patients with myelosuppressive chemotherapy (1, 8, (11) (12) (13) 16) . In a few patients, for reasons that are uncertain, the disease remits spontaneously (often requiring treatment at a later date) (4, 10) or runs an indolent course.
Factors with an impact on prognosis vary from one study to another. In one large series of patients over age 64, advanced stage disease, B symptoms, rash or pruritus, edema, and ascites were associated with a poor prognosis (8) . In other studies, lymphopenia (13) and B symptoms, patients over age 60 and anemia (12) were associated with a worse prognosis. Unfortunately, the features associated with a poor prognosis are among those most commonly associated with AIL-TCL.
Pathologic Features
Lymph nodes: histology, immunohistology, and genetic features
The classic appearance for lymph nodes involved by AIL-TCL consists of marked distortion of the normal architecture by a paracortical or diffuse proliferation of small lymphocytes, histiocytes, eosinophils, plasma cells, large lymphoid cells, and atypical, small to medium-sized lymphoid cells with clear cytoplasm associated with increased numbers of arborizing high endothelial venules. The clear cells tend to cluster around the blood vessels ( Fig. 1) . The large cells are usually immunoblasts. On occasion, large cells resemble Reed-Sternberg cells (Fig. 2 ). Burnt-out, hypocellular follicles may be present, or follicles may be absent (1, 6, 9, 14) . Rarely, cases with hyperplastic follicles have been described; such cases may progress over time to have a more typical appearance for AIL-TCL (4, 20) . The lymph nodes show a variable but often extensive extrafollicular proliferation of follicular dendritic cells (Figs. 1E, 3). Recently, it has been suggested that there is also a proliferation of desmin-positive fibroblastic reticulum cells (distinctive stromal cells with long cytoplasmic processes) in AIL-TCL (21) . The proliferation of dendritic processes often imparts a hypocellular quality to the infiltrate. Sinuses are usually obliterated, although the subcapsular sinus may remain patent in areas, even when the infiltrate extends into perinodal soft tissue. The distinctive clear cells in the polymorphous background that include small blood vessels and dendritic cells comprise the characteristic histologic picture of AIL-TCL. In some cases, however, clear cells are inconspicuous and the cytologic atypia of the T cells may be subtle, so that it may be difficult to make a diagnosis (7) .
In a recent study of AIL-TCL by Attygalle et al., (7) three different patterns were identified. In pattern I, hyperplastic follicles with poorly developed mantles and ill-defined borders were present, and the paracortex contained a mixed cellular infiltrate without an extrafollicular follicular dendritic cell proliferation. In pattern II, follicles were present but depleted of lymphoid cells, sometimes with a follicular dendritic cell proliferation extending beyond the follicles. In pattern III, normal architecture was effaced, with complete loss of recognizable follicles and a prominent extrafollicular proliferation of follicular dendritic cells (7) . In some cases, over time, sequential nodal biopsies show increased numbers of large neoplastic T cells (15) . In the study by Attygalle et al., progression from pattern II to pattern III (complete loss of follicles) was observed in two cases (7) . The neoplastic cells express pan-T-cell antigens, usually without "antigen loss," (4) although rarely CD5 ex-pression may be absent. Loss of CD7 has been described, although CD7 is not a true pan-T-cell antigen (16) . The neoplastic cells are T helper cells (CD4+) in most cases (Fig. 1C) , although there is an admixture of reactive CD8+ cells (6, 7, 9, 16, 22) . Recent observations suggest that the neoplastic cells are CD10+ (7,23) ( Fig. 1D ) and a subset are bcl-6+ (7, 20, 23) in almost all cases. Both CD10 and bcl-6 are well known as markers of follicle center B cells; their expression on the neoplastic cells of AIL-TCL confers an immunophenotype that is unique among T cells. It has been suggested that AIL-TCL may arise from outward migration from follicles and proliferation of the small, normal population of intrafollicular CD4+, CD10+, bcl-6+ T cells, a population that could possibly have a normal role in germinal center formation (20, 23) . The follicular dendritic cell proliferation can be highlighted with antibody to CD21, CD23, or CD35 (7, 9,21,23,24) ( Fig. 1E) .
Most of the immunoblasts (and Reed-Sternberg-like cells, when present) are B cells. In many cases, these large, transformed B cells harbor Epstein-Barr virus (EBV) (6, 7, 25) , which can be detected using immunostaining for EBV latent membrane protein or in situ hybridization for EBV-encoded RNA (EBER). Much less often, the EBV+ cells are said to be T cells (9, 25) . Rarely, the Reed-Sternberg-like cells also express CD15 and CD30, increasing their resemblance to true Reed-Sternberg cells (26) . The immunodeficiency associated with AIL-TCL is thought to permit the proliferation of the EBV-infected B cells (25, 26) . Also present are a variable number of small B cells and plasma cells expressing polytypic immunoglobulin.
Molecular genetic analysis reveals a monoclonal or oligoclonal proliferation of T cells in nearly all cases (4, 7, 9) . In some cases, no clone is identified, possibly due to a large number of admixed reactive cells or to an uneven distribution of neoplastic cells (22) . In a minority of cases (20% to 30% in several series) (4, 7, 9) ,a clonal population of B cells is also found. The clonal B cells are thought to represent a poorly controlled proliferation of the frequently EBV+ B immunoblasts (25, 27) . The characteristic tendency of AIL-TCL to harbor clonal or oligoclonal populations of T, and sometimes B cells suggests that this type of lymphoma may contain multiple clones of lymphoid cells, a distinctive feature (9) . In a few cases, a diffuse large B-cell lymphoma develops in patients with AIL-TCL; the lymphoma may represent a diffuse, clonal outgrowth of the EBV+ immunoblasts that are such a common finding in AIL-TCL (14, 28) .
Angioimmunoblastic T-cell lymphoma tends to have cytogenetic changes distinct from other peripheral T-cell lymphomas, including trisomy 3, trisomy 5, and gains of an X chromosome. Cytogenetic changes may have prognostic significance, with certain changes being associated with a better or worse outcome (10) .
Extranodal Sites
Histologic changes found in the spleen have only been described in a few cases. There may be nodular involvement of red or white pulp, or a diffuse infiltrate of lymphocytes, plasma cells, immunoblasts, and sometimes, eosinophils. Perifollicular fibrosis, burnt-out germinal centers, and infarcts have been described (1, 14) .
The bone marrow is usually hypercellular. In patients with hemolytic anemia, erythroid hyperplasia is frequent. In patients with a peripheral leukocytosis or an infection, the myeloid series may be hyperplastic, with a leftward shift. Lymphoma is more readily detected in core biopsies than on aspirate smears. Lymphomatous involvement is usually focal, but occasionally diffuse, and resembles the infiltrate seen in lymph nodes. When focal, the lymphoma is often paratrabecular (1, 13) .
Patients with cutaneous lesions in association with AIL-TCL have variably dense, often perivascular dermal lymphoid infiltrates. In one study, four different histologic patterns were observed (16) . In the first, a nonspecific, slight, superficial perivascular lymphocytic infiltrate with eosinophils, without atypia, was seen. In the second, there was a sparse superficial perivascular infiltrate with some atypical lymphoid cells and vascular hy- 3. The extrafollicular CD21+ dendritic cell proliferation is marked in this case in comparison with that found in case that was presented previously (Fig 1E) , in which it was less extensive (immunoperoxidase technique on a paraffin section). perplasia. In the third, there was a dense, diffuse, superficial and deep dermal infiltrate of atypical lymphoid cells, associated with vascular hyperplasia. In the fourth pattern, there was vasculitis without atypia of lymphoid cells. In this study, patients who had a clonal population of T cells in their cutaneous lesions that was identical to the clone found in their lymph nodes appeared to have a worse prognosis.
Differential Diagnosis
The differential diagnosis of AIL-TCL is broad, and includes reactive lymphoid hyperplasia, HD, large B-cell lymphoma (in particular T-cell rich large B-cell lymphoma (TCRBCL)), and peripheral T-cell lymphoma of other types (7, 11, 29, 30) . Among reactive processes, viral infection and autoimmune disorders have been specifically cited as posing problems in differential diagnosis (29, 30) . Distinguishing AIL-TCL from reactive hyperplasia can be difficult when there is early involvement of a lymph node by AIL-TCL, with partial nodal involvement with some preservation of normal architecture and a small proportion of neoplastic cells. Distinguishing AIL-TCL from reactive hyperplasia, HD, and B-cell lymphoma may be difficult when the cytologic atypia of the neoplastic T cells is subtle.
Clues that might suggest a reactive process include younger patient age and evidence of a specific infectious process, especially EBV infection, or an autoimmune disorder. Lymphadenitis due to EBV usually shows a predominance of CD8+ cells, rather than CD4+ cells. Reactive processes should not show the clear cells seen in AIL-TCL. The morphology of the burnt-out follicles of AIL-TCL overlaps with that of the hyaline-vascular follicles of Castleman's disease, except that in Castleman's disease, follicles have expanded, well-defined mantle zones. T-cell rich large B-cell lymphoma usually has a background composed of small lymphocytes and histiocytes, without the eosinophils and plasma cells often found in AIL-TCL. The B cells in the former disorder are EBV-negative, in contrast to the large B cells in many cases of AIL-TCL. The large B cells may show some morphologic and immunophenotypic overlap with the Reed-Sternberg cells of HD, and in both disorders, large cells may be EBV+. However, neither HD nor TCRBCL are characterized by atypical clear cells or burnt out germinal centers. Reactive disorders, HD, TCRBCL, and other peripheral T-cell lymphomas are not associated with extrafollicular proliferation of CD21+ dendritic processes.
The recent observation of coexpression of CD10 and bcl-6 by T cells in AIL-TCL may prove to be extremely helpful in differential diagnosis, as CD10+ and bcl-6+ T cells may well be unique to that type of lymphoma. Preliminary observations suggest that bcl-6 expression with- out CD10 may be found in peripheral T-cell lymphoma, not otherwise specified, but only a few cases have been studied (23) . Among peripheral T-cell lymphomas, AIL-TCL is the one most likely to harbor EBV-infected cells (31) . Molecular genetic analysis is often helpful in excluding reactive processes, HD, and B-cell lymphoma. Because there may be many scattered B cells outside of follicles in AIL-TCL, and because the neoplastic cells may express CD10 and bcl-6, like follicle center cells, it is possible that follicular lymphoma with diffuse areas would also enter the differential diagnosis. Attention to the distribution of B and T cells in comparison to the bcl-6+ and CD10+ cells is helpful in establishing a diagnosis ( Table 2) .
CONCLUSIONS
Angioimmunoblastic T-cell lymphoma is a T-cell lymphoma with distinctive clinical, histologic, immunohistologic, molecular genetic, and cytogenetic features. The most important recent advance in understanding and recognizing this lymphoma is the observation of CD10 and bcl-6 expression by the neoplastic T cells. The contemporary approach to diagnosis is based on histologic examination and review of appropriate immunostains (, , B and T-cell markers, CD10, bcl6, Epstein-Barr virus latent membrane protein, and in selected cases, CD15 and CD30), augmented when necessary by in situ hybridization for EBER and molecular genetic analysis. Because of AIL-TCL's mixed composition, flow cytometric analysis could give the misleading impression of a reactive process, and the results must be interpreted with caution. There has been a great deal of progress in defining the pathologic features of this disorder, but much more remains to be accomplished in order to devise effective therapy for this lymphoma.
